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S_qy Prolonged infusions of 5-fluorouracil (5-FU) have been used since the early 196s, but recntly
there has been a major of interest, party because of the advent of electronically controLed portable
infusion pumps. This paper ooks at the published data on continuously infused 5-FU in breast cancer. As a
single agent, bolus 5-FU has a response rate of around 25%; this inludes many patients in okler series who
were chemotherapy naie. The ovall response rate across all the studies with continuously infused 5-FU is
29%. However, the majority of these patients were heavily pretreated, and response rates of up to 54% have
been reported. What is more encouraging is the response rate in combination chemotherapy - even for
pretreated patients with metastatic diseas, response rates up to 89% have been found. However, this level of
benefit brings a new toxicity - pahmar-plantar and of course myelotoxicity still remains a
problem in the combination regimens. Randomised trials to assess the role of infusional 5-FU are now
indicated.
Fluorouracil (5-FU) has been used in the treatment of breast
cancer for over 30 years (Curreri et al., 1958) as adjuvant
therapy (Bonnadonna & Valagussa, 1989) as well as in the
treatment of metastatic disease (Ansfield et al., 1969). Used
as a single-agent bolus injection, response rates of 25-35%
have been reported (Ansfield et al., 1969; Carter, 1976),
whereas in combination with other cytotoxics higher response
rates are seen - up to 85% for example with the Duke AFM
regimen (Jones et al., 1990).
5-Fluorouracil is most commonly given as a bolus injec-
tion. There has been interest in the prolonged infusion of
5-FU since 1960 (Lemon, 1960; Sullivan et al., 1960). It was
known then that longer infusions produced less toxicity, and
so a higher total dose could be administered. This is because
of the altered pharmacology of the drug, in particular the
clarance is increased (Lemon, 1960; Collins et al., 1980;
Fraile et al., 1980). Furthermore, it has been shown that in
patients with metastatic colon cancer, there is a therapeutic
benefit of using continuous rather than bolus 5-FU (Lokich
et al., 1989).
Over the past few years there has been increasing interest
in the use of 5-FU infusions both intravenously and intra-
arterially in the treatment of liver metastases, particularly
from colon carcinoma. Such infusions have been both con-
tinuous, often until progressive disease or toxicity supervenes,
or for up to a few days, with a planned break between cycles.
Both approaches have been tried for breast cancer, but since
it is the prolonged continuous infusions which appear to be
associated with the very low myelotoxicity, this review will
confine its discussion to the clinical experience of this latter
approach.
Badcgro_
5-Fluorouracil was synthesised in 1957 by Heidelberger et al.
(1957). It was noted a few years earlier that rat hepatomas
use uracil as a substrate whereas normal cells do not, and it
was postulated that a fluorinated pyrimidine might therefore
be taken up selectively into neoplastic cells and be toxic to
them. The first clinical studies were arbitrarily done with the
drug being given over 5-8 days, somewhat ironic in view of
the recent resurgent interest in infusional rather than bolus
administration of the drug! The dose was ministered until
35 patients had toxicity, and overall nine responses were
noted, particularly in colon and breast carcinoma (3/5 for the
latter) (Curreri et al., 1958).
There are a number of good reviews of the pharmacology
of 5-FU (Pinedo & Peters, 1988; Grem, 1990), but a brief
mention of its mode of action will illustrate the arguments
for using prolonged infusions in the treatment of cancers.
There are two main pathways for the incorporation of 5-FU
into nucleic acids. It is metabolised initially to nucleotides
including fluoridine 5'-triphosphate (FUTP) and 5-fluoro-2'
deoxyuridine-5'-monophosphate (FdUMP), although it is
unclar which is the most important pathway clinically
(Grem, 1990). 5-Fluorouracil is inactivated initially by con-
version to 5-fluorodihydrouracil (see Figure 1) by the enzyme
dihydropyrimidine dehydrogenase (DHPD) (Woodcock et al.,
1980). This occurs in all tissues, but its activity is most
intense in the liver (Pinedo & Peters, 1988), which therefore
plays a major role in the degradation of 5-FU.
There have been case reports of severe 5-FU toxicity,
associated in some cases with an inherited DHPD deficiency
(Harris et al., 1991); such a deficiency has been shown to
result in reduced 5-FU clarance (Etienne et al., 1992). In the
clinical series discussed below, there is a noticeable variation
in the toxicity, and this could in part be due to inter-patient
variation in the metabolism of 5-FU.
T'he inhibition of thymidylate synthase (TS) is undoubtedly
one of its main mechanisms of action, since this leads to
depletion of TMP and thus inhibition of DNA synthesis. In
the presence of 5,10-CH2-tetrahydrofolate (THF), FdUMP
forms a tightly bound covalent bond with TS. Folinic acid
(5-formyl-tetrahydrofolate) is converted to 5,10-CH2-THF,
and thus causes stabilisation of the quaternary complex of
FdUMP bound to TS, hence the curre_. interest in increasing
FUMP
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Fuge 1 Metabolism of 5-FU (after Pinedo & Peters, 1988).
DHPD, dihydropyrimidine dehydroenase; F-DHU, 5-fluorodi-
hydrouracil; F-UPA, 5-fluoro-ureido propionate; FUdR, 5-
fluoro-2-deoxyridine; FUMP, 5-fluorouridine-5-monophosphate;
FUDP, 5-fluorouridine-5-diphosphate; FdUTP, 5-fluoro-2-deoxy-
uridine-5-triphosphate.
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the efficacy of 5-FU by the concomitant administration of
folinic acid (leucovorin). The other main mechanism of the
action of 5-FU is via its incorporation into RNA, after
conversion to FUTP. The nuclear RNA is then processed
into cytoplasmic rRNA, and this probably also contributes
to its cytotoxicity (Pinedo & Peters, 1988).
Administration of a bolus of 5-FU at a dose of between
300 and 600 mg m2 has been extensively studied (Collins et
al., 1980). There is a P half-life of 10-20 min, with rapid
elimination, with up to 50% hepatic extraction (Ensminger et
al., 1978). Total clearance is 0.5-21min-'. This results in
plasma levels above 1 gM for only a few hours, and this is the
level of normal cell toxicity (Cohen et al., 1974). In contrast,
continuous infusion of 5-FU results in a much higher clear-
ance of 2-61min ', which exceeds the hepatic blood flow.
This is explained by a high pulmonary extraction (Collins et
al., 1980).
There are perhaps two main reasons to consider using
5-FU in protracted infusion. The first is that, like other
antimetabolites which are specific for the S phase of the cell
cycle, 5-FU probably exerts much of its cytotoxicity only in
dividing cells. Most cancers are heterogeneous in respect of
mitotic activity, probably owing to differing numbers in Go
(Fisher et al., 1983). Thus to catch as many cells as possible
in S phase, prolonged infusion would seem to be optimal
(Vogelzang, 1984). Secondly a drug with a short-half life,
such as 5-FU, would require long-term infusion to permit
effective concentrations to be present in the malignant cells at
the time of replication (Vogelzang, 1984). Lokich et al. (1981)
was one of the first to develop continuous 5-FU in clinical
practice and, like Sullivan et al. in 1960, found that it was no
longer myelotoxicity that was dose limiting - rather stoma-
titis and a new syndrome of palmar-plantar erythrodysaes-
thesia (PPE) (Lokich & Moore, 1984). Fraile et al. (1980)
showed that a 96 h infusion of 5-FU resulted in 50- to
1,000-fold lower plasma and bone marrow concentrations of
the drug, as compared with similar doses administered as an
intravenous bolus, which may explain the reduced myelotox-
icity. Continuous infusion also permitted the administration
of larger total doses of drug (Lokich et al., 1981).
Clia s
Single-agent use
The first published data on the use ofcontinuous 5-FU in the
treatment of breast cancer came in a report of four patients
among 23 treated by Caballero et al. (1985) with 300 mg m2
day-'. Two partial responses were seen. Toxicity was only
briefly discussed (see Table I) and significant toxicity was
managed by a 5 day holiday from treatment; a second such
break in treatment prompted a dose reduction of 10-20%.
Hansen et al. (1987) reported 25 patients with metastatic
breast cancer treated with continuous 5-FU at 300 mg m-2
day-'. Four patients were started on doses of 200 or
250 mg m2 at the physician's discretion. Nmety-two per cent
of the patients had prior 5-FU exposure, and 'most' had
previously received chemotherapy for metastatic disease. The
overall response rate was 32% with one complete response
and, like most studies, treatment was continued until grade 2
ECOG toxicity or progression. Toxicity was significant but
tolerable, with a 10 day break in treatment and subsequent
dose reduction being necessary (and sufficient) in nine (36%)
patients (see Table I).
In 1988 Spicer et al. published details of the pharmaco-
kinetics of continuous 5-FU, treating 25 patients, including
six with breast cancer, using 300-500 mgm2 day-'. They
observed no dose-response effect, (either therapeutic or
toxic) despite a linear relationship between dose and steady-
state plasma level. Two out of the six patients receiving
350 mg m2 day-' developed mucositis, but none did at 300
or 450 mgm-2. At the peak dose of 500 mg m-2, four out of
seven patients developed mucositis within 3 weeks of starting
therapy; however, two patients were still being treated after 4
weeks without any significant toxicity. Both PPE and diar-
rhoea were also seen, again with no correlation between dose
and time of onset. They concluded that patients should be
treated with 450 mgmM2 day-'.
In 1989 three more series were published. Huan et al.
(1989) reported on 28 women with metastatic disease given
175-250 mg m-2 day-'; the dose varied according to the
extent of prior therapy. The overall response rate was 54%,
which was as good in those with visceral disease as those
without. Interestingly the different doses did not have much
impact on response (see Table I). Toxicity was considerable
(see Table I), and included three patients with ataxia that
took 4 weeks to resolve, unlike the other epithelial toxicities,
which resolved within 2 weeks.
Jabboury et al. (1989a) reported on 36 patients treated
initially with 250mgm2, of whom 32 were evaluable for
response. All had had prior 5-FU exposure, and, in com-
parison with the other series, the patients were more heavily
pretreated. There was an overall response rate of only 16%.
Toxicities were similar to the other studies (see Table I).
However, two patients suffered haemolysis (with a positive
direct Coombs test) and the authors noted a progressive rise
in the median erythrocyte mean cell volume from 97 fl before
treatment to a maximal of 104fl. Reductions of 50 mgm2
were instituted for toxicity requiring a break in treatment,
but equally the dose was increased by 50 mg m-2 if there was
no significant toxicity after 4 weeks. Following an initial
prevalence of mucocutaneous toxicity of 68%, an elective
interruption of treatment for 3-7 days every 4 weeks was
instituted for the final 11 patients in the study. Only one of
these patients developed oral mucositis, a difference that was
highly significant (P = 0.002).
Table I Single-agent continuous 5-FU in breast cancer
Toxicity -grade 2 (%)
Response (%) Myelosup- Median duration
Reference No. Dose CR PR SD PPE Oral NIVID pression (months)
Caballero et al. (1985) 4 300 0 50 25 48 52 0 0
Hansen et al. (1987) 25 200-300 4 28 24 36 16 12 0 6
Spicer et al. (1988) 6 300-500 0 4 0 13 25 17 4
Strauss et al. (1988) 11 300 0 27 0 Unspecified
Hatfeld et al. (1989) 25 250-300 0 28 0 Unspecified 4
Huan et al. (1989) 13 250 8 46 0'A
13 200 8 39 0 29 36 11 7 4+
2 175 0 100
Jabboury et al. (1989) 32 250-400 3 12 63 18 38 3 6 4
Chang et al. (1989) 10 200-300 0 30 30 10 40 50 0 2
Berlie et al. (1990) 27 175-300 0 12 27 24 30 24
Van Hoef et al. (1991) 8 300 0 25 50 10 23 53 0
Ng et al. (1994) 23 200 0 35 26 4 0 0 4
Overall 199 2 27
CR, complete response; PR, partial response; SD, stable disease; PPE, palmar-plantar erythrodysaesthesia; N, nausea; V, vomiting; D, diarrhoea.122 D.A. CAMERON et al.
Chang et al. (1989) reported on ten patients, refractory to
other chemo- and endocrine therapies, who received 200-300
mgm2 (according to performance status). There were three
partial responses and one patient with bone metastases 'im-
proved'. Toxicity was similar (see Table I), although one
patient who died later of brain metastases developed ataxia.
The authors found dose-limiting toxicity even at 200 mg m-2,
but felt that continuous 5-FU was appropriate palliative
therapy.
A series of 25 patients treated with doses between 250 and
300 mg m-2 was reported by Hatfield et al. (1989). The
patients were relatively heavily pretreated, with an average of
2.64 regimens per patient. There was a partial response rate
of 28%, including two patients who survived for over 30
months. There was a non-significant increase in median sur-
vival from 4 to 6 months for the responders. Toxicity was
'manageable'.
Berlie et al. (1990) reported on 33 'evaluable' patients
treated with between 175 and 300mgm-2day-', and obtain-
ed a partial response rate of 12% (see Table I for toxicity),
although it appears only 27 patients were fully evaluable, one
was non-evaluable and the rest had a fall in CA 15.3.
A Dutch group reported in 1991 on 36 patients treated
with 300mgm2 day-' until grade 2 toxicity or progression
(van Hoef et al., 1991). The group included eight evaluable
patients with breast cancer, all of whom had been pretreated.
Two patients developed sclerosis of bone metastases, with
reduction of pain for 6-9 months; we have classified them as
partial responders in our overall analysis. A further four were
'stabilised' for between 5 and 11 weeks. Toxicities (grade 1 or
higher) are shown in Table I.
Our own experience with continuous 5-FU mirrors the
later, less optimistic reports (Ng et al., 1994). We treated 23
patients with metastatic breast cancer, 20 of whom had had
previous chemotherapy. Partial responses were seen in eight
(35%) of the patients, with a median duration of 12 weeks.
Responses were particularly seen in locoregional disease -
9/11 patients had some form of response, but only three
(25%) met criteria for partial response. Toxicity was gener-
ally less than in many reported series (see Table I).
As can be seen from these studies, PPE is a major toxicity
with prolonged infusional 5-FU, but there is some evidence
that it can be ameliorated by the use ofhigh-dose pyridoxine.
In a study of folinic acid potentiation of weekly 5-FU for
patients with metastatic cancer, including five with breast
cancer, Mortimer and Anderson (1990) found a prevalence of
PPE of 27%. Eleven out of 14 of these patients were treated
with oral pyridoxine 150 mg daily, and in all the symptoms
resolved within 1 week. There was no loss of tumour res-
ponse in those given pyridoxine; indeed, the authors noted
that they were able to avoid dose reductions of the 5-FU.
The rationale for this is the observation that the clinical
appearance was similar to that of acrodynia in pyridoxal
phosphate-depleted rodents (Gyorgy & Eckharck, 1939). This
was confirmed in a randomised study by Beveridge et al.
(1990), who treated patients with either 100 mg daily or
nothing. They noted significant improvement in PPE in the
treated patients, but no change in the oral mucositis. How-
ever, they saw no fewer dose interruptions for those given
pyridoxine, and did not comment on any change in response.
Folinic acid
As stated earlier, there has been recent interest in increasing
the efficacy of 5-fluorouracil by adding exogenous folinic
acid. This is because it stabilises the quaternary complex of
5-FdUMP and thymidylate synthase, and as such may be
clinically and experimentally similar to continuously infused
5-FU (Lokich & Anderson, 1993). Many clinical trials have
been carried out in colon, breast and other tumours to see if
the overall response rate can be improved. Results are
conflicting; a good review of the rationale and results for
these trials is given by Grem et al. (1987). However, there are
few data on leucovorin and continuous 5-FU; 15 patients
were treated with 225-300mgm-2day'1 continuous 5-FU
and oral leucovorin at 5 mg m-2 day-' (Tempero et al.,
1991). In all cases the limiting toxicity was stomatitis or
diarrhoea. Partial response rates included the single patient
with breast cancer. Jabboury et al. (1989b) administered
200mgm-2day-' of folinic acid together with continuous
5-FU at 200 mg m-2 day-'. However, mucocutaneous tox-
icity became dose limiting after 8 days, requiring a median
break in treatment of 6 days. Despite this they saw a 60%
response rate in the 22 women with breast cancer.
Combination chemotherapy
More recently there have been reports of the use of con-
tinuous 5-FU in combination with other agents, of which the
first was by Lokich et al. (1985), who combined it with
methotrexate.
Gordon and Baker (1990), reviewing the role of protacted
infusion of chemotherapy in breast cancer, reported on their
expeience with the FAXI regime, and this was updated at
ASCO in the same year (Gordon et al., 1990). A dose of
250 mg m-2 day-' of 5-FU was given continuously with
weekly bolus doxorobicin at 15 mgm2 and cyclophos-
phamide 70 mg m-2. Doses were altered to obtain a safe
nadir, and the 5-FU dose was reduced if grade 2 or higher
stomatitis was seen. Twenty-seven of the 37 patients were
evaluable, with an overall response rate of 82%, which was
not affected by prior chemotherapy. Mucositis was the major
dose-limiting toxicity, with 82% having interruptions and
dose reductions of the 5-FU to 200 mgm-2 day-'. At this
lower dose, no patients had had mucositis after 5 weeks'
treatment (see Table II for summary).
In 1988 Strauss et al. reported on 21 previously treated
patients. Continuous 5-FU at 300mgm2day-' was given to
all, and ten were also given cisplatinum 20mgm2 week-',
for at least 6 weeks. Overall they had 48% partial response
rate of 3-15 months' duration, but this was increased to
70% for those also given cisplatinum. Toxicity was 'modest'
(see Table H).
The combination of weekly cisplatinum and etoposide has
also been given together with continuous 5-FU at 200 mg
m-2day-' (Saphner et al., 1991). The CDDP and VP16 were
administered weekly as boluses in weeks 2-8, and then fort-
nightly thereafter. There were at most 12 evaluable patients
with breast cancer, including one complete and one partial
response. At the dose level they recommended (which was
unspecified in the abstract), toxicity was both mucocutaneous
Table k Continuous 5-FU in combination chemotherapy for breast cancer
Response (%) Toxiciry>grade 3 (%)
No. Drugs CR PR SD PPE Oral N/VD MWyelosuppression
Strauss et al. (1988) M 10 C 0 79 - Not specified
Gordon & Baker (1990) M 27 A CX 15 67 15 - 85 - 56 Saphner et al. (1991) M <12 C E 8 8 - Notspecified
Gabra et al. (1993) M 27 A 33 56 - 32 55 0 23 Iveson et al. (1993) M 28 C E 21 64 _ 32 2 24 22 LA 13 C E 38 54 1 42
Bowman (unpublisbed) LA 26 A 27 40 - 27 23 15 4 Smithetal.(1993) NA 34 C E 65 - - 11 3 20 31
M, metastatic; LA, locally advanced; NA, neoadjuvant; A, doxorubicin; C, cisplatinum; CX, cyclophosphamide; E, epirubicin.CONTINUOUS 5-FU IN BREAST CANCER 123
and myelosuppression, including grade 4 thrombocytopenia
and leucopenia. Percentages were not given.
We have also used a dose of 200mgm2day-' 5-FU in
the treatment of metastatic breast cancer, combining it in a
dose-escalating study with doxorubicin (20-30 mg m2
week-') for 12 weeks (Gabra et al., 1993) in a regimen called
AcF. A total of 27 patients have been treated to date (55%
of whom have been previously treated), and the majority are
younger women with visceral metastases. The overall res-
ponse rate has been 89%, with a complete response rate of
33%, which is higher than that reported for Duke's AFM for
the equivalent group of patients (Jones et al., 1990). Table II
summanizes the toxicities seen.
The Royal Marsden Breast Group (O'Brien et al., 1992;
Iveson et al., 1993) has combined 200mgm2day-' con-
tinuously infused 5-FU with 60 mgm2 cisplatinum and
50mgm2 epirubicin administered every 3 weeks, based on
the use of same regimen in gastric cancer (Findlay & Cunn-
ingham, 1993). Patients with primary inoperable tumours as
well as metastatic disease were included. Table II shows the
response rates and toxicities, which are better for the non-
metastatic group (92% vs 75%), although no details of prior
chemotherapy are given for the patients with metastatic
disease. Significant neurological toxicity was seen (52% for
all grades), and included at least one case of ataxia (O'Brien
et al., 1992).
Encouraged by these results, the use of this regimen was
extended to 6 months of therapy for patients with potentially
operable primary breast tumours of at least 3 cm diameter
(Smith et al., 1993). Thirty-four patients were evaluable; all
had an objective response, with 22 (65%) exhibiting complete
clinical responses. Median time to response was 25 days.
Only one patient required a mastectomy at the end of
therapy, but the pathological response rate amongst the 15
having wide local excisions was not stated. Severe toxicity
(WHO grade 3/4) was acceptable (see Table II).
In respect of neoadjuvant treatment we have treated
patients with T4 tumours with 12 weeks of 5-FU at 200 mg
m-2 day-', together with weekly bolus doxorubicin 20-30
mgm-2 (A. Bowman, personal communication). To date 26
patients have been enrolled, of whom ten are still under
study. Of the 16 who have completed treatment, 15 are
evaluable, and there have been four complete responses
(27%) and six partial responses (40%). Only one patient
progressed on the treatment. Toxicity has not been incon-
siderable but always reversible (see Table II).
ComchHions
5-Fluorouracil has an established role in the treatment of
breast cancer, and it is important to determine its best mode
of administration. Continuous intravenous administration is
obviously feasible with the use of continuous ambulatory
electronic pumps, and the reported series had few serious
problems with either the semipermanent central lines or the
pumps. Single-agent bolus 5-FU does not seem to have much
of a role in the treatment of breast cancer (Rubens, 1991),
and this is partly related to the low response rate, as well as a
belief that combination chemotherapy offers, in general,
better palliation. The overall response rate in the published
series of continuous single-agent 5-FU is about 29%, with a
complete response rate of only 2% (Table I). For almost all
these patients this was at least second-line therapy; and this
response rate compares well with the 16% seen in a similar
group of 249 patients given a variety of regimens at Guy's
Hospital, London (Gregory et al., 1993).
For this modest gain in response a new side-effect of PPE
emerges, and this can be quite distressing for the patients. In
addition, there is a inconvenience to the patient of having
continuously infused chemotherapy, as well as the increase in
expense related to the use of pumps. Any mechanical device
can fail, and although our own experience is that the biggest
problem is battery failure there is concern about the variation
in dose infused during the 7 days of the 5-FU infusion.
As regards the optimal dose, 200 mg m-2 is active, but is
not without side-effects. Huan et al.'s paper of 1989 shows no
significant difference between 200 and 250 mgm-2. The
majority of the published data are based on doses of 300 mg
m-2 day-', and yet none of the studies with the higher doses
betters Huan et al.'s overall response rate of 54%. Certainly
much higher doses (e.g. 500mgm2day-') seem to result in
increased toxicity, as seen by Spicer et al. (1988). What has
not been looked at in depth is whether the approach of a
short break in treatment every few weeks [as used by Jab-
boury et al. (1989a) and Lokich et al. (1993)J would allow
higher doses or perhaps the same responses but with much
less toxicity. If one could thus significantly reduce the
mucocutaneous toxicity, but without altering the clinical res-
ponse, it would make the treatment ideal for palliation,
particularly as Chang et al. (1989) have shown that it can
overcome a lack of response to bolus 5-FU.
Combination chemotherapy is the commonest approach
for metastatic disease. It would therefore be very interesting
to look in detail at the role of infusional 5-FU in a tradi-
tional regimen, such as CAF or CMF, bearing in mind the
high response rates noted in Table II. Obviously what is
needed is a comparison, and we are currently undertaking
such a randomised study to look at the role of continuous
5-FU within CMF for metastatic breast cancer.
The Marsden group have extended their use of ECF
(Smith et al., 1993) to the truly adjuvant situation. This is an
interesting development for continuous 5-FU with combina-
tion chemotherapy. For patients with poor-prognosis breast
cancer at presentation, largely as defined by having >10
positive axillary nodes, it would be interesting to examine the
role of regimens such as the Marsden's ECF and our AcF,
possibly even as an induction prior to high-dose chemo-
therapy with stem cell rescue (Peters et al., 1993). It is,
however, probably premature to challenge the gold standard
of adjuvant CMF (Henderson & Shapiro, 1991) for those
with lower numbers of axillary nodes.
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